Search

Your search keyword '"I. Abdulkader"' showing total 203 results

Search Constraints

Start Over You searched for: Author "I. Abdulkader" Remove constraint Author: "I. Abdulkader"
203 results on '"I. Abdulkader"'

Search Results

1. Pancreatic fusocellular sarcoma: The importance of endoscopic ultrasound-guided fine needle aspiration in the differential diagnosis of solid pancreatic tumors Sarcoma fusocelular de páncreas: importancia de la PAAF guiada por ultrasonografía endoscópica en el diagnóstico diferencial de los tumores sólidos pancreáticos

2. Quiste de duplicación gástrico: diagnóstico por punción-aspiración guiada por ecoendoscopia Adult gastric duplication cyst: diagnosis by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)

3. Immunohistochemical expression of VEGFR1 in non small cell lung carcinomas: Lower VEGFR1 expression is asociated with squamous cell carcinoma subtype and high SUV max values in 18F-FDG PET

4. Expresión inmunohistoquímica de VEGFR1 en carcinomas de pulmón de células no pequeñas: La expresión inferior de VEGFR1 se asocia con el subtipo de carcinoma de células escamosas y los valores elevados en SUVmáx en PET de 18F-FDG

5. CURING CONDITIONS INFLUENCE ON SOME ENGINEERING PROPERTIES OF LIME-TREATED EXPANSIVE CLAYEY SOIL FROM MOSUL AREA

6. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC

8. Immunohistochemical expression of VEGFR1 in non small cell lung carcinomas: Lower VEGFR1 expression is asociated with squamous cell carcinoma subtype and high SUV max values in

9. Immunohistochemical expression of VEGFR1 in non small cell lung carcinomas: Lower VEGFR1 expression is asociated with squamous cell carcinoma subtype and high max SUV values in

11. P-89 Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy

12. P-89 Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy

13. Global injury morbidity and mortality from 1990 to 2017: Results from the global burden of disease study 2017

14. Estimating global injuries morbidity and mortality: Methods and data used in the Global Burden of Disease 2017 study

17. Estimating global injuries morbidity and mortality: Methods and data used in the Global Burden of Disease 2017 study

18. Global injury morbidity and mortality from 1990 to 2017: Results from the global burden of disease study 2017

19. Erratum: Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6))

20. EP1.09-17 Spanish Lung Cancer Biomarker Testing Registry (Lungpath): Descriptive Analysis Focus in ALK Traslocation Results

21. EP1.09-17 Spanish Lung Cancer Biomarker Testing Registry (Lungpath): Descriptive Analysis Focus in ALK Traslocation Results

22. Erratum: Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6))

23. Erratum: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7))

24. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017

25. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017

26. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

27. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017

28. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017

29. P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients

30. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017

31. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017

32. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017

33. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017

34. Erratum: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7))

35. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017

36. Airway Reconstruction Surgical Dissection Manual

37. Comparison Between EUS-Guided 19G and 22G Procore Needle Biopsies in Pancreatic Masses: a Prospective Multicenter Study in 72 Cases

38. Spindle cell variant of papillary thyroid carcinoma

39. PROSPECTIVE MULTICENTER EVALUATION OF A NOVEL 22-G ECHO-TIP PROCORE HISTOLOGY EUS-NEEDLE IN PATIENTS WITH A SOLID PANCREATIC MASS

40. Amiloidosis renal como manifestación clínica inicial de la enfermedad de Crohn

41. [The immunohistochemical expression of cyclin B1 is associated with higher SUV in 18F-FDG-PET in non-small cell lung cancer patients. Initial results]

42. [The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results]

43. Pneumonitis caused by silicone gel following breast implant rupture

44. [Tumors in sternocleidomastoid muscle]

45. [The autoimmune hepatitis-primary biliary cirrhosis overlap syndrome: a case report]

46. Rhinosporidiosis in Qatar: A Case Report and Literature Review

47. Síndrome overlap hepatitis autoinmune-cirrosis biliar primaria: a propósito de un caso

48. [Gum tumor in a patient with background of hepatic cirrhosis]

49. [Pelvic mass in a patient with background of mycosis fungoid]

50. Histological evaluation of chronic pancreatitis by endoscopic ultrasound‐guided fine needle biopsy

Catalog

Books, media, physical & digital resources